MedTrace Logo

Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Stem Cell Transplant

NCT02088840 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2769

Last updated 2021-08-20

No results posted yet for this study

Summary

All patients undergoing autologous or allogeneic stem cell transplant (SCT) for any underlying disease will be monitored for severe infections by gram negative bacteria (SIGNB) during the engraftment period. The follow up will be stopped at 4 months from the day of transplant. About 50 transplant centers will be involved in the study.

Conditions

  • Complications of Organ Transplant Stem Cells
  • Gram-Negative Bacterial Infections

Sponsors & Collaborators

  • Gruppo Italiano Trapianto di Midollo Osseo

    lead OTHER

Principal Investigators

  • Corrado Girmenia, MD · Policlinico Umberto I - Rome

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02088840 on ClinicalTrials.gov